BIOVF News and Press, Swedish Orphan Biovit Ord From 12/14/20

The drug portfolio of Alexion Pharmaceuticals (ALXN) is led by C5-inhibitors: Ultomiris (ALXN1210/ravulizumab-cwvz) and Soliris (eculizumab). In the wake of its proposed merger with AstraZeneca (AZN), even clinical-stage biopharmaceutical companies focused on complement-mediated therapies hav...

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval for Swedish Orphan Biovitrum's or SOBI (BIOVF) Doptelet (avatrombopag) for the treatment of primary chronic immune thrombocytopenia, an autoimmune disorder characterised by ...

Apellis Pharmaceuticals (APLS) and Sobi Swedish Orphan Biovitrum AB (BIOVF) announce positive top-line results at Week 48 from the Phase 3 PEGASUS study, which demonstrated sustained hematological and clinical improvements in patients with paroxysmal nocturnal hemoglobinuria ((PNH)) who were ...

Realising opportunities for future growth and financial update: Sobi Capital Markets Day 2020 STOCKHOLM , Dec. 10, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI ) is hosting a virtual Capital Markets Day today. Presentations fro...

Apellis Pharmaceuticals (APLS) and Swedish Orphan Biovitrum (BIOVF) having commenced dosing of the first patients in registrational Phase 2 MERIDIAN study of pegcetacoplan in ~200 adults with sporadic amyotrophic lateral sclerosis ((ALS)), a neurodegenerative disease that leads...

After re-examining its its initial negative opinion issued in July, the European Medicines Agency's advisory group CHMP maintains its position against approving Swedish Orphan Biovitrum AB's (BIOVF) Gamifant (emapalumab) for the treatment of primary hemophagocytic lymphohistiocytosis, a rare ...

Sobi launch Doptelet® (avatrombopag) in Europe PR Newswire STOCKHOLM, Nov. 4, 2020 STOCKHOLM , Nov. 4, 2020 /PRNewswire/ -- Sobi™ Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI ) today announced the commercial launch of Doptelet&#...

Apellis Pharmaceuticals (APLS) and Swedish Orphan Biovitrum (BIOVF) have collaborated to accelerate the advancement of systemic pegcetacoplan, a targeted C3 therapy.Sobi will receive global co-development and exclusive ex-US commercialization rights for systemic pegcetacoplan, while Apel...

Swedish Orphan Biovitrum AB (BIOVF) Q3 2020 Earnings Conference Call October 22, 2020 07:00 AM ET Company Participants Guido Oelkers - CEO Henrik Stenqvist - CFO Ravi Rao - Head of R&D and CMO Conference Call Participants Eun Yang - Jefferies Emily Field - Barclays Christopher Uhde - SEB ...

The following slide deck was published by Swedish Orphan Biovitrum AB (publ) in conjunction with their 2020 Q3 earnings call. For further details see: Swedish Orphan Biovitrum AB (publ) 2020 Q3 - Results - Earnings Call Presentation